USANA Health Sciences (USNA)
(Real Time Quote from BATS)
$37.65 USD
+0.37 (0.99%)
Updated Sep 12, 2024 11:24 AM ET
4-Sell of 5 4
A Value F Growth A Momentum B VGM
Income Statements
Fiscal Year end for USANA Health Sciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 921 | 999 | 1,186 | 1,135 | 1,061 |
Cost Of Goods | 177 | 194 | 218 | 209 | 188 |
Gross Profit | 744 | 805 | 969 | 926 | 873 |
Selling & Adminstrative & Depr. & Amort Expenses | 651 | 697 | 798 | 749 | 727 |
Income After Depreciation & Amortization | 93 | 108 | 170 | 176 | 146 |
Non-Operating Income | 10 | 1 | 1 | 2 | 4 |
Interest Expense | 0 | 0 | 0 | 1 | 0 |
Pretax Income | 102 | 109 | 171 | 178 | 151 |
Income Taxes | 39 | 39 | 54 | 53 | 50 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 64 | 69 | 117 | 125 | 101 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 64 | 69 | 117 | 125 | 101 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 113 | 129 | 192 | 199 | 169 |
Depreciation & Amortization (Cash Flow) | 20 | 21 | 22 | 23 | 23 |
Income After Depreciation & Amortization | 93 | 108 | 170 | 176 | 146 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 19.35 | 19.31 | 20.34 | 21.26 | 22.82 |
Diluted EPS Before Non-Recurring Items | 3.30 | 3.59 | 5.73 | 5.86 | 4.41 |
Diluted Net EPS (GAAP) | 3.30 | 3.59 | 5.73 | 5.86 | 4.41 |
Fiscal Year end for USANA Health Sciences, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 212.87 | 227.80 | 221.08 | 213.37 | 238.20 |
Cost Of Goods | 40.33 | 43.07 | 42.32 | 42.53 | 43.33 |
Gross Profit | 172.54 | 184.73 | 178.76 | 170.84 | 194.88 |
SG&A, R&D, and Dept/Amort Expenses | 154.70 | 160.06 | 154.55 | 153.23 | 170.48 |
Income After SG&A, R&D, and Dept/Amort Expenses | 17.84 | 24.67 | 24.21 | 17.61 | 24.40 |
Non-Operating Income | 2.41 | 2.49 | 2.54 | 2.97 | 2.45 |
Interest Expense | 0.05 | 0.05 | 0.15 | 0.04 | 0.04 |
Pretax Income | 20.20 | 27.11 | 26.61 | 20.53 | 26.81 |
Income Taxes | 9.77 | 10.57 | 9.85 | 9.18 | 9.52 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 10.43 | 16.54 | 16.77 | 11.35 | 17.29 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 10.43 | 16.54 | 16.77 | 11.35 | 17.29 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 19.16 | 19.30 | 19.25 | 19.37 | 19.43 |
Diluted EPS Before Non-Recurring Items | 0.54 | 0.86 | 0.87 | 0.59 | 0.89 |
Diluted Net EPS (GAAP) | 0.54 | 0.86 | 0.87 | 0.59 | 0.89 |